Embecta price to free cash flow EMBC
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Nov 2, 2026
- 2.1×
- 4-year median
- 12.1×
- Against its 4-year history
- 12th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.9× to 95.5×
- Peer median
- 12.3×
Embecta's price to free cash flow is 2.1× as of Nov 2, 2026.
That is below its 4-year median of 12.1×, lower than on 88% of days in the last 4 years.
Over that time it ranged from 0.9× in Jun 2026 to 95.5× in Jul 2024.
The median for 10 medical instruments and supplies stocks of a similar size is 12.3×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.1× | 0.9× | 4.1× |
| 2025 | 3.9× | 3.8× | 59.9× |
| 2024 | 60.5× | 23.6× | 95.5× |
| 2023 | 26.3× | 3.4× | 26.3× |
| 2022 | 3.7× | 3.7× | 4.0× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Embecta's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| EMBCEmbecta | 2.1× |
| INFUInfuSystem | 12.0× |
| TCMDTactile Systems Technology | 19.3× |
| UTMDUtah Medical Products | 19.6× |
| PDEXPro DEX | 17.3× |
| MOVMovado | 10.0× |
| IRMDIradimed | 38.9× |
| IARTIntegra Lifesciences | 12.3× |
| BVSBioventus | 11.7× |
| STAAStaar Surgical | n/m |
| KEQUKewaunee Scientific | 8.9× |
| Peer median | 12.3× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Embecta
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.